Results 291 to 300 of about 89,248 (335)
Some of the next articles are maybe not open access.

Emerging anxiolytics

Expert Opinion on Emerging Drugs, 2007
Anxiety disorders are the most common of the psychiatric disorders and are also associated with significant economic costs and impaired work productivity. The first-line pharmacotherapy of pharmatherapy for a number of anxiety disorders comprises selective serotonin re-uptake inhibitors (SSRIs) and serotonin and noradrenaline re-uptake inhibitors ...
Nirvana S, Pillay, Dan J, Stein
openaire   +2 more sources

Buspirone: Anxiolytic?

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985
Sixty (60) out-patients with DSM III generalized anxiety disorder were treated after a 1-week placebo washout in a 4-week double-blind study with buspirone, diazepam and placebo; after which they were withdrawn abruptly from medication or assigned to a 2-week period of placebo.
J C, Pecknold   +5 more
openaire   +2 more sources

Is barakol anxiolytic?

Behavioural Pharmacology, 1998
A recent report suggested that barakol, a biologically active extract of the south-east Asian plant, Cassia siamea, has anxiolytic properties. The purpose of the present study was to replicate and extend these findings by examining the dose-response effects of barakol (0-20 mg/kg) in two pharmacologically validated tests of rat anxiety: the elevated ...
D. F. Fiorino   +4 more
openaire   +3 more sources

Hypnosedatives and Anxiolytics

2008
Hypnosedatives and Anxiolytics are commonly prescribed drugs. This chapter presents an overview of adverse effects of hypnosedatives and anxiolytics published in recent years. This chapter covers some benzodiazepines (Alprazolam, Clobazam, Clonazepam, Clonazepam, Diazepam, Midazolam, and Lorazepam), benzodiazepine-like drugs (Eszopiclone, Zaleplon ...
Stephen Curran   +2 more
openaire   +2 more sources

Pregabalin: a new anxiolytic

Expert Opinion on Investigational Drugs, 2003
Pregabalin (S-[+]-3-isobutylgaba) was designed as a lipophilic GABA (gamma-aminobutyric acid) analogue substituted at the 3'-position in order to facilitate diffusion across the blood-brain barrier. It was originally developed as an anticonvulsant agent, however it has been shown to be effective in the treatment of several disorders including ...
Robert Pohl, Bianca Lauria-Horner
openaire   +2 more sources

Home - About - Disclaimer - Privacy